<DOC>
	<DOCNO>NCT02708914</DOCNO>
	<brief_summary>The primary objective study evaluate 1:1 dose conversion Eprex速 UB-851 term clinical efficacy safety subject chronic renal failure receive hemodialysis .</brief_summary>
	<brief_title>Study Compare Safety Efficacy UB-851 Eprex速</brief_title>
	<detailed_description>This 52-week , phase III trial consist two part : Part I design double-blind , randomize , multicenter , parallel-group study evaluate efficacy safety UB-851 comparison Eprex速 subject renal anemia hemodialysis treatment period 24 week . Part II design single-arm , safety evaluation period ( week 25 week 52 ) evaluate long-term safety immunogenicity UB-851 .</detailed_description>
	<mesh_term>Anemia</mesh_term>
	<mesh_term>Epoetin Alfa</mesh_term>
	<criteria>Main 1 . Subjects sign informed consent undergo study procedure . 2 . Subjects age 20 85 year . 3 . Hemodialysis subject chronic renal failure renal anemia outpatient clinic currently stable Eprex速 treatment administer intravenous injection ( 1 3 time per week ) least 3 month prior randomization . Main 1 . Maintenance epoetin dose &gt; 300 IU/kg per week . 2 . Treatment longacting epoetin analogue . 3 . Detectable antierythropoietin antibody clinical symptom screen visit , history Pure Red Cell Aplasia ( PRCA ) .</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>March 2016</verification_date>
</DOC>